Patient info Open main menu

Cinacalcet Abdi 90 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
90 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Cinacalcet Abdi 90 mg film-coated tablets

1. What Cinacalcet Abdi is and what it is used for

Cinacalcet Abdi works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorus in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).

Cinacalcet Abdi is used in adults:

  • to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.
  • to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid cancer.
  • to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.

Cinacalcet Abdi is used in children aged 3 years to less than 18 years of age:

  • to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.

In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroids glands. “Primary” means that the hyperparathyroidism is not caused by any other condition and “secondary” means that the hyperparathyroidism is caused by another condition, e.g., kidney disease. Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.

2. What you need to know before you take Cinacalcet Abdi

Do not take Cinacalcet Abdi

  • if you are allergic to cinacalcet or any of the other ingredients of this medicine (listed in section 6).
  • if you have low levels of calcium in your blood. Your doctor will monitor your blood calcium levels.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Cinacalcet Abdi

Before you start taking Cinacalcet Abdi, tell your doctor if you have or have ever had:

  • seizures (fits or convulsions). The risk of having seizures is higher if you have had them before;
  • liver problems;
  • heart failure.

Cinacalcet Abdi reduces calcium levels. Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in adults and children treated with cinacalcet.

Please tell your doctor if you experience any of the following which may be signs of low calcium levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, confusion or loss of consciousness while being treated with Cinacalcet Abdi.

Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines known to cause heart rhythm problems, while taking cinacalcet.

For additional information see section 4.

During treatment with Cinacalcet Abdi, tell your doctor:

  • if you start or stop smoking, as this may affect the way cinacalcet works.

Children and adolescents

Children under the age of 18 with parathyroid cancer or primary hyperparathyroidism must not take Cinacalcet Abdi.

If you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium levels before starting treatment with Cinacalcet Abdi and during treatment with Cinacalcet Abdi. You should inform your doctor if you experience any of the signs of low calcium levels as described above.

It is important that you take your dose of Cinacalcet Abdi as advised by your doctor.

Other medicines and Cinacalcet Abdi

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines particularly etelcalcetide or any other medicines that lower the level of calcium in your blood.

You should not receive Cinacalcet Abdi together with etelcalcetide.

Tell your doctor if you are taking the following medicines.

Medicines such as these can affect how Cinacalcet Abdi works:

  • medicines used to treat skin and fungal infections (ketoconazole, itraconazole and voriconazole);
  • medicines used to treat bacterial infections (telithromycin, rifampicin and ciprofloxacin);
  • a medicine used to treat HIV infection and AIDS (ritonavir);
  • a medicine used to treat depression (fluvoxamine).

Cinacalcet Abdi may affect how medicines such as the following work:

  • medicines used to treat depression (amitriptyline, desipramine, nortriptyline and clomipramine);
  • a medicine used to relieve cough (dextromethorphan);
  • medicines used to treat changes in heart rate (flecainide and propafenone);
  • a medicine used to treat high blood pressure (metoprolol);

Cinacalcet Abdi with food and drink

Cinacalcet Abdi should be taken with or shortly after food.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Cinacalcet has not been tested in pregnant women. In case of pregnancy, your doctor may decide to modify your treatment, as cinacalcet might harm the unborn baby.

It is not known whether cinacalcet is excreted in human milk. Your doctor will discuss with you if you should discontinue either breast-feeding or treatment with Cinacalcet Abdi.

Driving and using machines

Dizziness and seizures have been reported by patients taking cinacalcet. If you experience these side effects, do not drive or operate machines.

Cinacalcet Abdi contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Cinacalcet Abdi

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will tell you how much cinacalcet you must take.

Cinacalcet Abdi must be taken orally, with or shortly after food. The tablets must be taken whole and are not to be chewed, crushed or divided.

Cinacalcet is also available as granules for paediatric use. Children who require doses lower than 30 mg, or who are unable to swallow tablets should receive Cinacalcet granules .

Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.

If you are being treated for secondary hyperparathyroidism

The usual starting dose for Cinacalcet Abdi in adults is 30 mg (one tablet) once per day.

The usual starting dose of Cinacalcet Abdi for children aged 3 years to less than 18 years of age is no more than 0.20 mg/kg of body weight daily.

If you are being treated for parathyroid cancer or primary hyperparathyroidism

The usual starting dose for Cinacalcet Abdi is 30 mg (one tablet) twice per day.

If you take more Cinacalcet Abdi than you should

If you take more Cinacalcet Abdi than you should you must contact your doctor immediately. Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures.

If you forget to take Cinacalcet Abdi

Do not take a double dose to make up for a forgotten dose.

If you have forgotten a dose of Cinacalcet Abdi, you should take your next dose as normal.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Please tell your doctor immediately:

  • If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. These may be signs that your calcium levels are too low (hypocalcaemia).
  • If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).

Very common: may affect more than 1 in 10 people

  • nausea and vomiting, these side effects are normally quite mild and do not last for long.

Common: may affect up to 1 in 10 people

  • dizziness
  • numbness or tingling sensation (paraesthesia)
  • loss (anorexia) or decrease of appetite
  • muscle pain (myalgia)
  • weakness (asthenia)
  • rash
  • reduced testosterone levels
  • high potassium levels in the blood (hyperkalaemia)
  • allergic reactions (hypersensitivity)
  • headache
  • seizures (convulsions or fits)
  • low blood pressure (hypotension)
  • upper respiratory infection
  • breathing difficulties (dyspnoea)
  • cough
  • indigestion (dyspepsia)
  • diarrhoea
  • abdominal pain, abdominal pain – upper
  • constipation
  • muscle spasms
  • back pain
  • low calcium levels in the blood (hypocalcaemia).

Not known: frequency cannot be estimated from available data

  • Hives (urticaria)
  • Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).
  • Unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).

After taking cinacalcet a very small number of patients with heart failure had worsening of their condition and/or low blood pressure (hypotension).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system (see contact details below). By reporting side effects you can help provide more information on the safety of this medicine.

United Kingdom

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

5. How to store Cinacalcet Abdi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Cinacalcet Abdi contains

  • The active substance is cinacalcet. Each film-coated tablet contains 30mg, 60mg or 90mg of cinacalcet (as hydrochloride).
  • The other ingredients are lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, magnesium stearate and talc.
  • The tablet coating contains hypromellose, titanium dioxide (E171), lactose monohydrate, triacetin, yellow iron oxide (E172) and indigo carmine lake (E132).

What Cinacalcet Abdi looks like and contents of the pack

Cinacalcet Abdi is a light green film-coated tablet. They are oval-shaped and have ‘C’ marked on one side and ‘30’, ‘60’ or ‘90’ on the other side.

Cinacalcet Abdi is available in blisters of 30 mg, 60 mg or 90 mg film-coated tablets. Each blister pack contains either 14, 28 or 84 tablets in a carton.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Abdi Farma GmbH

Donnersbergstraße 4

64646 Heppenheim

Germany

Manufacturer

S.C. Polisano Pharmaceuticals S.A., Alba Iulia Road 156, 550052 Sibiu, Sibiu County, Romania

Meditrial Internationals Ltd.,

Iztok Distr., 3 Charles Darwin Str.,

Sofia 1113,

Bulgaria

The medicinal product is authorized in the Member States of the EEA under the following names:

Name of the Member StateName of the medicinal product
DenmarkCinacalcet Accord 30/60/90 mg filmovertrukne tabletter
ItalyCinacalcet Abdi 30/60/90 mg compressa rivestita con film
NetherlandsCinacalcet Accord 30/60/90 mg filmomhulde tabletten
SwedenCinacalcet Accord 30/60/90 mg filmdragerad tablet
United KingdomCinacalcet Accord 30/60/90 mg film-coated tablets
FinlandCinacalcet Accord 30/60/90 mg kalvopäällysteiset tabletit
EstoniaCinacalcet Accord 30/60/90 mg õhukese polümeerikattega tabletid
IcelandCinacalcet Accord filmuhúðaðar töflur
LithuaniaCinacalcet Accord plėvele dengtos tabletės
LatviaCinacalcet Accord apvalkotās tabletes
NorwayCinacalcet Accord 30/60/90 mg filmdrasjerte tabletter

This leaflet was last revised in 06/2024.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 56740/0030

Last revision stated in the text: June 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Cinacalcet Abdi 90 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Cinacalcet
Strength 90 mg
Pharmaceutical form Oral tablet
Light green, oval, biconvex film-coated tablet of 14.05-14.45 mm length debossed ‘C’ on one side and ‘90’ on the other.
SUMMARY OF PRODUCT CHARACTERISTICS
How is it taken Oral
Excipients lactose monohydrate, cellulose, microcrystalline, starch, pregelatinized (maize), crospovidone, magnesium stearate, talc, hypromellose, titanium dioxide (E171), triacetin, yellow iron oxide (E172), Indigo carmine lake (E132)
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Calcium homeostasis, anti-parathyroid agents
  1. H Systemic hormonal preparations, excl. sex hormones and insulins
    1. H05 Calcium homeostasis
      1. H05B Anti-parathyroid agents
        1. H05BX Other anti-parathyroid agents
          1. H05BX01 cinacalcet
Marketing authorisation PL 56740/0030 (first authorised 17 September 2020)
Marketing authorisation holder Abdi Farma GmbH
Codes BNF 09050102

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.